The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 7, 2004, Pages 749-754

  Marchal, L ^a   D'Haens, G ^a   Van Assche, G ^a   Vermeire, S ^a   Noman, M ^a   Ferrante, M ^a   Hiele, M ^a   Bueno De Mesquita, M ^a   D'Hoore, A ^a   Penninckx, F ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY;

ABSCESS; ADOLESCENT; ADULT; AGED; ANEMIA; ARTHRITIS; ARTICLE; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; FEMALE; FEVER; FISTULA; HOSPITALIZATION; HUMAN; ILEUS; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PERITONITIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL TECHNIQUE; UPPER RESPIRATORY TRACT INFECTION; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 11144357651     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01904.x     Document Type: Article

References (11)

1. van Deventer SJ. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51: 18-22.
2. Hommes DW, van Deventer SJ. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr Opin Clin Nutr Metab Care 2000; 3: 191-5.
3. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 1029-35.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
5. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-9.
7. Sands B, van Deventer S, Bernstein C, et al. Long-term treatment of fistulizing Crohn's disease: response to infliximab in the Accent II trial through 54 weeks. Gastroenterology 2002; 122: A81(Abstract).
8. Centocor. Remicade Safety Experience. Clinical Trial and Post Marketing Data. PSUR7. Malvern, PA: Centocor. 2003: data on file.
9. Brzezinski A, Armstrong L, Alvarez Del Real G, et al. Infliximab does not increase the risk of complications in the peri-operative period in patients with Crohn's disease. Gastroenterology 2002; 122(4): W1363.
10. Colombel JF, Loftus EV, Tremaine WJ, et al. Perioperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease. Gastroenterology 2002; 124: A521(Abstract).
11. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-7.